Genmab — August 2017
-
En emission er da lige til højrebenet, vil ikke opgive deres 50/50 hvis det kører på skinner. Men marketingsmæssigt vil GB og SG være som to humlebier i flyvekonkurrence med en condor, så der skal nok blive futtet en masse unødige penge af i den proces er mit gæt.
-
-
I am hopeful that they will have it in the clinics soon. I can’t really say because, that program is fully outlicensed to them and we are just watching them as they progress it. Yes, we are very excited to see that one can get in the clinic very soon.
-
-
Jeg fandt 8 bcma-rettede car-t studier på ct: https://clinicaltrials.gov/ct2/results?cond=&term=car-t+and+bcma&cntry1=&state1=&Search=Search Og har stadig ikke helt forstået, hvad det er Kite og Bluebird kan patentere. At udtage T-celler, omprogrammere, og genindsætte dem, står vel enhver frit for?
-
Nogen der har kommentarer til denne?
http://www.nasdaq.com/press-release/cellectar-biosciences-clr-131-achieves-overall-survival-of-greater-than-22-months-in-advanced-20170808-00803
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind